Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V 1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
The limbic localization of the arginine vasopressin V 1b receptor has prompted speculation as to a potential role of this receptor in the control of emotional processes. To investigate this possibility, we have studied the behavioral effects of SSR149415, the first selective and orally active non-peptide antagonist of vasopressin V 1b receptors, in a variety of classical (punished drinking, elevated plus-maze, and light/dark tests) and atypical (fear/anxiety defense test battery and social defeat-induced anxiety) rodent models of anxiety, and in two models of depression [forced swimming and chronic mild stress (CMS)]. When tested in classical tests of anxiety, SSR149415 produced anxiolytic-like activity at doses that ranged from 1 to 30 mg/kg (i.p. or p.o.), but the magnitude of these effects was overall less than that of the benzodiazepine anxiolytic diazepam, which was used as a positive control. In contrast, SSR149415 produced clear-cut anxiolytic-like activity in models involving traumatic stress exposure, such as the social defeat paradigm and the defense test battery (1–30 mg/kg, p.o.). In the forced swimming test, SSR149415 (10–30 mg/kg, p.o.) produced antidepressant-like effects in both normal and hypophysectomized rats. Moreover, in the CMS model in mice, repeated administration of SSR149415 (10 and 30 mg/kg, i.p.) for 39 days improved the degradation of the physical state, anxiety, despair, and the loss of coping behavior produced by stress. These findings point to a role for vasopressin in the modulation of emotional processes via the V 1b receptor, and suggest that its blockade may represent a novel avenue for the treatment of affective disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat
Pellow, S., Chopin, P., File, S. E., & Briley, M. (1985) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(85)90031-7 · Cited by 5,822
Depression: a new animal model sensitive to antidepressant treatments
PORSOLT, R. D., LE PICHON, M., & JALFRE, M. (1977) · Nature · doi:10.1038/266730a0 · Cited by 4,451
Neurocircuitry of stress: central control of the hypothalamo–pituitary–adrenocortical axis
Herman, J. P., & Cullinan, W. E. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)10069-2 · Cited by 2,270
Chronic mild stress-induced anhedonia: A realistic animal model of depression
Willner, P., Muscat, R., & Papp, M. (1992) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(05)80194-0 · Cited by 1,160
A simple and reliable conflict procedure for testing anti-anxiety agents
Vogel, J. R., Beer, B., & Clody, D. E. (1971) · Psychopharmacologia · doi:10.1007/bf00403989 · Cited by 841
Ethopharmacological analysis of rat behavior on the elevated plus-maze
Cruz, A. P. M., Frei, F., & Graeff, F. G. (1994) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(94)90472-3 · Cited by 823
de Vries, G. J., & Buijs, R. M. (1983) · Brain Research · doi:10.1016/0006-8993(83)90855-7 · Cited by 565
Molecular cloning and expression of a rat Via arginine vasopressin receptor
Morel, A., O'Carroll, A.-M., Brownstein, M. J., & Lolaft, S. J. (1992) · Nature · doi:10.1038/356523a0 · Cited by 477
Animal models for the study of anti-anxiety agents: A review
Treit, D. (1985) · Neuroscience & Biobehavioral Reviews · doi:10.1016/0149-7634(85)90046-6 · Cited by 450
Miczek, K. A. (1979) · Psychopharmacology · doi:10.1007/bf00426664 · Cited by 397
Research works printed but not linked: 3
- D De Wied J Endocrinol 48, xlv–xlvi (1970).
- R Dantzer, R M Bluthe Crit Rev Neurobiol 6, 243–255 (1992).
- J Simiand, P E Keane, M C Barnouin, M Keane, P Soubrié, G Le Fur Fundam Clin Pharmacol 7, 413–427 (1993).
Cited by
Items 101–200 of 524
Models of Depression: Unpredictable Chronic Mild Stress in Mice
Nollet, M. (2021) · Current Protocols · doi:10.1002/cpz1.208 · Cited by 122
Current investigational drugs for major depression
Kulkarni, S. K., & Dhir, A. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902880850 · Cited by 122
“Vasopressin V(1b) receptor s are located in the limbic region of the brain, thus playing an important role in the control of emotional processes [174].”
BackgroundOpen questions in current models of antidepressant action
Tanti, A., & Belzung, C. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00585.x · Cited by 109
“Indeed, in rodents, CRF1 and V1b antagonists are effective both in models of depression and in models of pathological anxiety (Griebel et al., 2002; Ducottet et al., 2003; Louis et al., 2006; Salome et al., 2006).”
BackgroundSerotonin receptor 4 in the hippocampus modulates mood and anxiety
Karayol, R., Medrihan, L., Warner‐Schmidt, J. L., Fait, B. W., Rao, M. N., Hölzner, E., Greengard, P., Heintz, N., & Schmidt, E. F. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00994-y · Cited by 120
Laugeray, A., Launay, J., Callebert, J., Surget, A., Belzung, C., & Barone, P. R. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.02.014 · Cited by 120
Endocrine disturbances in depression
Tichomirowa, M. A., Keck, M. E., Schneider, H. J., Páez-Pereda, M., Renner, U., Holsboer, F., & Stalla, G. K. (2005) · Journal of Endocrinological Investigation · doi:10.1007/bf03345535 · Cited by 118
Involvement of melanocortin-4 receptor in anxiety and depression
Chaki, S., & Okuyama, S. (2005) · Peptides · doi:10.1016/j.peptides.2004.11.029 · Cited by 118
Overview of cellular electrophysiological actions of vasopressin
Raggenbass, M. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.11.074 · Cited by 117
“The vasopressin V1B receptor antagonist SSR149415 appears to exert anxiolytic- and antidepressant-like effects (Griebel et al., 2002; Stemmelin et al., 2005).”
BackgroundNeural Substrates of Psychostimulant Withdrawal-Induced Anhedonia
D’Souza, M. S., & Markou, A. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_20 · Cited by 116
“Furthermore, the nonpeptide V1b receptor antagonist SSR149415 exerted antidepressant-like effects in rodents (Griebel et al. 2002).”
BackgroundSavić, B., Murphy, D., & Japundžić‐Žigon, N. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.858941 · Cited by 116
Faster, better, stronger: Towards new antidepressant therapeutic strategies
O’Leary, O. F., Dinan, T. G., & Cryan, J. F. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.046 · Cited by 115
“Several preclinical studies suggest that the non-peptide V1B receptor antagonist, SSR149415, has antidepressant-like behavioural effects (Breuer et al., 2009; Griebel et al., 2002; Iijima and Chaki, 2007), although negative findings have also been reported (Hodgson et al.”
BackgroundOxytocin and vasopressin: genetics and behavioral implications
Caldwell, H. K., & Young, W. S. (2006) · Handbook of Neurochemistry and Molecular Neurobiology · doi:10.1007/978-0-387-30381-9_25 · Cited by 113
Stemmelin, J., Lukovic, L., Salome, N., & Griebel, G. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300562 · Cited by 112
“In cases of a significant main effect, post hoc comparisons were performed with a Dunnett test.”
BackgroundMethodInfluentialSelf-citationHippocampal Neurogenesis, Depressive Disorders, and Antidepressant Therapy
Païzanis, E., Hamon, M., & Lanfumey, L. (2007) · Neural Plasticity · doi:10.1155/2007/73754 · Cited by 109
Edwards, S., Guerrero, M. A., Ghoneim, O. M., Roberts, E., & Koob, G. F. (2011) · Addiction Biology · doi:10.1111/j.1369-1600.2010.00291.x · Cited by 109
“…by the anxiolytic- and antidepressant-like effects of the small molecule V1b vasopressin receptor antagonist SSR149415 (nelivaptan (2S,4R)-1-[(3R)-5-chloro-1(2,4-dimethoxyphenyl)sulfonyl-3-(2-methoxyphenyl)-2oxo-indolin-3-yl]-4-hydroxy-N,N-dimethyl-pyrrolidine2-carboxamide; Griebel et al. 2002).”
BackgroundInfluentialBelzung, C. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2013.342 · Cited by 106
Mesfin, M., Asres, K., & Shibeshi, W. (2014) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-14-310 · Cited by 106
Depression and antidepressants: molecular and cellular aspects
Lanni, C., Govoni, S. M., Lucchelli, A., & Boselli, C. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0055-x · Cited by 106
“The involvement of the V1b receptor subtype is supported by experimental evidence using SR149415, a selective V1b antagonist, at this time in phase II clinical trials in patients with anxiety and MDD (Table 2) [142].”
MethodOshikawa, S., Tanoue, A., Koshimizu, T.-A., Kitagawa, Y., & Tsujimoto, G. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.3.623 · Cited by 105
“Pharmacological studies showed that it inhibits the exogenous AVP-induced increase in circulating corticotropin and produces anxiolytic- and antidepressant-like effects (Griebel et al., 2002; Serradeil-Le Gal et al., 2002a,b).”
BackgroundAVP V selective antagonist SSR149415 blocks aggressive behaviors in hamsters
Blanchard, R. J., Griebel, G., Farrokhi, C. B., Markham, C. M., YANG, M., & Blanchard, D. C. (2004) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2004.10.024 · Cited by 104
“Both in vitro and in vivo SSR149415 potently inhibited AVP-induced activity and reduced emotion-linked behavior in a variety of mouse models after both acute and repeated administration (Griebel et al., 2002).”
BackgroundResultInfluentialSelf-citationLitvin, Y., Murakami, G., & Pfaff, D. W. (2011) · Physiology & Behavior · doi:10.1016/j.physbeh.2011.03.007 · Cited by 104
“In fact, preclinical studies show that anxiolytics such as chlordiazepoxide (Librium), paroxetine (Paxil) and buspirone (Buspar) decrease preproAVP (the uncleaved precursor to AVP) mRNA expression in the rat brain [8]; 3) Chronic stressors such as the chronic social defeat regimen employed here, produce a shift from C…”
InfluentialMelatonin treatment mimics the antidepressant action in chronic corticosterone‐treated mice
Crupi, R., Mazzon, E., Marino, A., Spada, G. L., Bramanti, P., Cuzzocrea, S., & Spina, E. (2010) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2010.00775.x · Cited by 103
“considered as an index of a depressed-like state as described elsewhere [18].”
BackgroundMethodMak, P., Broussard, C., Vacy, K., & Broadbear, J. H. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111416687 · Cited by 95
“Reductions in anxiety-related behavior in the EPM have also been reported following intraperitoneal administration of AVP1A (e.g. Bleickardt et al., 2009) and AVP1B (e.g. Griebel et al., 2002) antagonists, with similar results found in AVP gene-knockout mice (Bielsky et al., 2004).”
ResultThe vasopressin 1b receptor and the neural regulation of social behavior
Stevenson, E. L., & Caldwell, H. K. (2012) · Hormones and Behavior · doi:10.1016/j.yhbeh.2011.11.009 · Cited by 100
Mice with Mutations in the HPA-System as Models for Symptoms of Depression
Müller, M. B., & Holsboer, F. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.008 · Cited by 99
Dempster, E. L., Burcescu, I., Wigg, K., Kiss, E., Baji, I., Gadoros, J., Tamás, Z., Kennedy, J. L., Vetró, A., Kovacs, M., et al. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.10.1189 · Cited by 99
Signs of attenuated depression-like behavior in vasopressin deficient Brattleboro rats
Mlynarik, M., Zelena, D., Bagdy, G., Makara, G. B., & Ježová, D. (2006) · Hormones and Behavior · doi:10.1016/j.yhbeh.2006.12.007 · Cited by 98
“Present finding points out the role of endogenous vasopressin in triggering depression-like behavior in FST that is consistent with previously described antidepressant potential of vasopressin V1b receptor antagonist in this test (Griebel et al., 2002).”
BackgroundResultInfluentialGriebel, G., Stemmelin, J., Lopez-Grancha, M., Boulay, D., Boquet, G., Slowinski, F., Pichat, P., Beeské, S., Tanaka, S., Mori, A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-54557-5 · Cited by 97
Self-citationEngin, E., & Treit, D. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.03.020 · Cited by 97
“…the neuropharmacological specificity of such effects complicates the intense, ongoing research effort to discover neuropeptides, or their synthetic derivatives, that can serve as novel agents for the treatment of human anxiety disorders (e.g., Griebel et al., 2002; Holmes et al., 2003).”
Is AD a Stress-Related Disorder? Focus on the HPA Axis and Its Promising Therapeutic Targets
Canet, G., Hernandez, C., Zussy, C., Chevallier, N., Desrumaux, C. M., & Givalois, L. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00269 · Cited by 96
Pan, Y., Kong, L., Li, Y., Xia, X. H., Kung, H., & Jiang, F.-X. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.04.009 · Cited by 96
Claudine, S.-L. G., Derick, S., Brossard, G., Maurice, M., Simiand, J., Rolf, G., Griebel, G., & Guillon, G. (2003) · Stress · doi:10.1080/1025389032000114524 · Cited by 96
“Neither did the drug modify sleep patterns following EEG analysis nor impair learning in the Morris water maze up to 30 mg/kg in mice or rats (Griebel et al., 2002).”
BackgroundSelf-citationElevated plasma arginine vasopressin levels in veterans with posttraumatic stress disorder
de Kloet, C. S., Vermetten, E. H. G. J. M., Geuze, E., Wiegant, V. M., & Westenberg, H. G. M. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.11.009 · Cited by 94
Alexander, S., Mathie, A. A., & Peters, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01649_3.x · Cited by 93
Involvement of vasopressin in affective disorders
Surget, A., & Belzung, C. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.11.065 · Cited by 90
Griebel, G., Stemmelin, J., Gal, C. S., & Soubrié, P. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612053764797 · Cited by 90
“, for 2 days Active at 10 and 30 Imipramine, fluoxetine [49]”
BackgroundMethodInfluentialSelf-citationSalomé, N., Stemmelin, J., Cohen, C., & Griebel, G. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0424-1 · Cited by 89
“For example, microinjection of the benzodiazepine, midazolam, or of the 5-HT1A agonist, 8-OH-DPAT, elicited anxiolytic-like effects in the elevated plus- or T-maze ( Green and Vale 1992; Pesold and Treit 1995; Gonzalez et al. 1996; Zangrossi et al. 1999).”
BackgroundMethodSelf-citationZhou, Y., Leri, F., Cummins, E., Hoeschele, M., & Kreek, M. J. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301419 · Cited by 89
“In fact, acute stress increases extracellular levels of arginine vasopressin (AVP) in the rat amygdala and hypothalamus (Ebner et al, 2002; Wigger et al, 2004), and activation of V1b receptors by AVP modulates anxiogenic and depressive behaviors in rats (Griebel et al, 2002; Wigger et al, 2004).”
InfluentialSciolino, N. R., Bortolato, M., Eisenstein, S. A., Fu, J., Oveisi, F., Hohmann, A. G., & Piomelli, D. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.04.007 · Cited by 89
“Behavioral measures included the time spent in open and closed arms and frequency of head dips and stretched-attend postures, as described by Griebel et al., (2002).”
MethodJutkiewicz, E. M., Wood, S. K., Houshyar, H., Hsin, L., Rice, K. C., & Woods, J. H. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2164-z · Cited by 89
“Also, the CRF-R1 antagonists antalarmin and SSR125543A decreased the duration of immobility in the forced swim test in rats, indicating an antidepressant-like effect with these compounds (Griebel et al. 2002a).”
BackgroundDepression Shows Divergent Effects on Evoked and Spontaneous Pain Behaviors in Rats
Shi, M., Wang, J., & Luo, F. (2010) · Journal of Pain · doi:10.1016/j.jpain.2009.07.002 · Cited by 87
Hodgson, R. A., Higgins, G. A., Guthrie, D. H., Lu, S. X., Pond, A. J., Mullins, D. E., Guzzi, M. F., Parker, E. M., & Varty, G. B. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.12.021 · Cited by 86
New horizons for therapeutics in drug and alcohol abuse
Jupp, B., & Lawrence, A. J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.11.002 · Cited by 85
Sturm, M., Becker, A., Schroeder, A., Bilkei‐Gorzó, A., & Zimmer, A. (2015) · Genes Brain & Behavior · doi:10.1111/gbb.12208 · Cited by 83
“A worsening of the coat state due to either metabolic changes or a depression-induced reduction of grooming behavior has been regarded an indicator for a depression-like emotional state (Griebel et al. 2002; Santarelli et al. 2003).”
BackgroundResearch in anxiety disorders: From the bench to the bedside
Garner, M. J., Möhler, H., Stein, D. J., Mueggler, T., & Baldwin, D. S. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.01.011 · Cited by 83
Gross, M., & Pinhasov, A. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.10.049 · Cited by 83
Griebel, G., Stemmelin, J., Lopez‐Grancha, M., Fauchey, V., Slowinski, F., Pichat, P., Dargazanli, G., Abouabdellah, A., Cohen, C., & Bergis, O. E. (2018) · Scientific Reports · doi:10.1038/s41598-018-20895-z · Cited by 82
Self-citationGriebel, G., Beeské, S., & Stahl, S. M. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m07804 · Cited by 81
Self-citationShimazaki, T., Iijima, M., & Chaki, S. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.06.032 · Cited by 81
Aggressive Behavior Linked to Corticotropin-Reactive Autoantibodies
Fetissov, S. O., Hallman, J., Nilsson, I. A. K., Lefvert, A., Oreland, L., & Hökfelt, T. G. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.081 · Cited by 81
Ducottet, C., Aubert, A., & Belzung, C. (2004) · Behavioural Brain Research · doi:10.1016/j.bbr.2004.04.020 · Cited by 80
de Andrade, J. S., Céspedes, I. C., Abrão, R. O., Santos, T. B., Diniz, L., Britto, L. R. G., Spadari-Bratfisch, R. C., Ortolani, D., Melo-Thomas, L., da Silva, R. C. B., et al. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.04.031 · Cited by 79
Schüle, C., Baghai, T. C., Eser, D., & Rupprecht, R. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.52 · Cited by 73
A Hypomorphic Vasopressin Allele Prevents Anxiety-Related Behavior
Bunck, M., Czibere, L., Horvath, C., Graf, C., Frank, E., Kessler, M. S., Murgatroyd, C., Müller‐Myhsok, B., Gonik, M., Weber, P., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005129 · Cited by 77
Bahí, A. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.03.010 · Cited by 76
Anxiolytic-like effects of mitragynine in the open-field and elevated plus-maze tests in rats
Hazim, A. I., Ramanathan, S., Parthasarathy, S., Mustapha, M., & Mansor, S. M. (2014) · The Journal of Physiological Sciences · doi:10.1007/s12576-014-0304-0 · Cited by 75
“Flumazenil (10 mg/kg) was intraperitoneally administered 15 min before the test [12].”
Classical and novel approaches to the preclinical testing of anxiolytics: A critical evaluation
Haller, J., Aliczki, M., & Gyimesi-Pelczer, K. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.09.001 · Cited by 74
for the National Institute on Alcohol Abuse and Alcoholism Clinical Investigations Group (NCIG) Study Group, Ryan, M. L., Falk, D. E., Fertig, J. B., Rendenbach-Mueller, B., Katz, D. A., Tracy, K. A., Strain, E. C., Dunn, K. E., Kampman, K., et al. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.214 · Cited by 72
Oxytocin and vasopressin: signalling, behavioural modulation and potential therapeutic effects
Rae, M., Lemos Duarte, M., Gomes, I., Camarini, R., & Devi, L. A. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15481 · Cited by 72
“Furthermore, animals treated with V1B receptor antagonist had anxiolytic effects in the EPM and light/dark box tests (Griebel et al., 2002).”
Characterization of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behavior
Bleickardt, C. J., Mullins, D. E., MacSweeney, C. P., Werner, B. J., Pond, A. J., Guzzi, M. F., Martin, F. D. C., Varty, G. B., & Hodgson, R. A. (2009) · Psychopharmacology · doi:10.1007/s00213-008-1354-x · Cited by 71
“Of these, the V1b receptor has been most widely investigated for its potential role in anxiety ( Griebel et al. 2002; Serradeil-Le et al. 2005; Hodgson et al. 2007).”
BackgroundBortolotto, V., Cuccurazzu, B., Canonico, P. L., & Grilli, M. (2014) · BioMed Research International · doi:10.1155/2014/612798 · Cited by 71
Jarcho, M. R., Mendoza, S. P., Mason, W. A., Yang, X., & Bales, K. L. (2011) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2010.00677.x · Cited by 70
“While this contradicts our predictions, previous work has suggested that at some dosages AVP may be anxiogenic (Bielsky et al. 2004; Griebel et al. 2002; Landgraf et al. 1995).”
ResultVasopressin, Central Autonomic Control and Blood Pressure Regulation
Lozić, M., Šarenac, O., Murphy, D., & Japundžić‐Žigon, N. (2018) · Current Hypertension Reports · doi:10.1007/s11906-018-0811-0 · Cited by 70
Separation-induced ultrasonic vocalization in rat pups: Further pharmacological characterization
Iijima, M., & Chaki, S. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.11.005 · Cited by 70
SALOME, N., Stemmelin, J., Cohen, C., & Griebel, G. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.03.013 · Cited by 69
“…similar to that observed with SSR149415, a V1b receptor antagonist, which displays anxiolytic-like effects in classical (punished drinking and elevated plus-maze) and atypical (fear/anxiety defense test battery, social defeat-induced anxiety) rodent models of anxiety (Griebel et al., 2002, 2003).”
MethodSelf-citationGenetic, epigenetic and environmental impact on sex differences in social behavior
Shepard, K. N., Michopoulos, V., Toufexis, D. J., & Wilson, M. E. (2009) · Physiology & Behavior · doi:10.1016/j.physbeh.2009.02.016 · Cited by 56
“Antagonism of the AVP V1a and V1b receptors [170,173,174] or CRH1 or CRH2 receptors [175–181] reduces anxiety in both rodent and non-human primate models, indicating that these neuropeptides are involved in stressinduced anxiety and depression [170,182,183].”
BackgroundDiabetes Insipidus: Celebrating a Century of Vasopressin Therapy
Qureshi, S., Galiveeti, S., Bichet, D. G., & Roth, J. (2014) · Endocrinology · doi:10.1210/en.2014-1385 · Cited by 67
Vasopressin & Oxytocin in Control of the Cardiovascular System: An Updated Review
Japundžić‐Žigon, N., Lozić, M., Šarenac, O., & Murphy, D. (2019) · Current Neuropharmacology · doi:10.2174/1570159x17666190717150501 · Cited by 67
Crupi, R., Mazzon, E., Marino, A., Spada, G. L., Bramanti, P., Battaglia, F., Cuzzocrea, S., & Spina, E. (2011) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-11-7 · Cited by 66
“The animal protocol was approved by the Institutional Animal Care and Use Committee (Council directive # 87-848, October 19, 1987, Ministère de l’Agriculture et de la Forêt, Service Vétérinaire de la Santé et de la Protection Animale, permission # 92-256 to D.J.D.).”
Lemmens‐Gruber, R., & Kamyar, M.-R. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-006-6054-2 · Cited by 66
Interaction of Stress, Corticotropin-Releasing Factor, Arginine Vasopressin and Behaviour
Beurel, E., & Nemeroff, C. B. (2014) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2014_306 · Cited by 64
“For example, there is an antagonist of V1 receptors (SSR149415) that has shown anxiolytic, antidepressant and anti-stress effects (Griebel et al., 2002; Hodgson et al., 2007; Iijima and Chaki, 2007; Litvin et al., 2011; Overstreet and Griebel, 2005; Shimazaki et al., 2006; Simon et al., 2008; Stemmelin et al., 2005; U…”
BackgroundEgashira, N., 三島, 健., Iwasaki, K., Oishi, R., & Fujiwara, M. (2009) · Journal of Pharmacological Sciences · doi:10.1254/jphs.08r14fm · Cited by 64
Sebaai, N., Lésage, J., Breton, C., Vieau, D., & DELOOF, S. (2004) · Neuroendocrinology · doi:10.1159/000078098 · Cited by 64
Griffante, C., Green, A., Curcuruto, O., Haslam, C. P., Dickinson, B. A., & Arban, R. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706383 · Cited by 64
“…they are also significantly expressed in CNS areas such as hippocampus, frontal, piriform and cingulate cortex, caudate putamen, medial habenula, central amygdala and hypothala- mus (Lolait et al., 1995; Hernando et al., 2001; Griebel et al., 2002; Stemmelin et al., 2005).”
BackgroundInfluentialOxytocin and vasopressin modulate the social response to threat: a preclinical study
Bowen, M. T., & McGregor, I. S. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000388 · Cited by 63
Hypothalamic vasopressin system regulation by maternal separation: Its impact on anxiety in rats
Zhang, L., Hernández, V. S., Liu, B., Medina‐Pizarro, M., Nava-Kopp, A. T., Irles, C., & Morales, M. A. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.03.046 · Cited by 64
“Likewise, a recent report has found that the systemic administration of a non-peptide V1b antagonist (SSR149415) is able to produce anxiolytic effects in classical (EPM, VCT) and atypical rat models of anxiety, suggesting a crucial role of AVP V1b receptor in the production of anxiogenic states (Griebel et al., 2002).”
BackgroundAulinas, A., Plessow, F., Asanza, E., Silva, L. E., Marengi, D. A., Fan, W., Abedi, P., Verbalis, J. G., Tritos, N. A., Nachtigall, L. B., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02608 · Cited by 60
Overstreet, D. H., & Griebel, G. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.07.021 · Cited by 60
“The findings for the swim test confirm previous conclusions that SSR149415 had antidepressant-like effects (Griebel et al., 2002; Alonso et al., 2004).”
BackgroundMethodResultInfluentialSelf-citationDiaz, S. L., Narboux‐Nême, N., Boutourlinsky, K., Doly, S., & Maroteaux, L. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.12.012 · Cited by 59
“The assessment of the coat state is a valid outcome to evaluate reduced self-care because stressed mice pay less attention to hygienic behaviors, and the fur get unkempt (Diaz and Maroteaux, 2015; Griebel et al., 2002; Santarelli et al., 2003).”
Kim, T.-K., Lee, J. E., Kim, J., Park, J. Y., Choi, J., Kim, H., Lee, E. H., & Han, P. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9160-z · Cited by 59
Zhou, Y., Proudnikov, D., Yuferov, V., & Kreek, M. J. (2010) · Brain Research · doi:10.1016/j.brainres.2009.11.015 · Cited by 58
Zhou, Y., Colombo, G., Carai, M. A. M., Ho, A., Gessa, G. L., & Kreek, M. J. (2011) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2011.01532.x · Cited by 57
“…in the rat amygdala and hypothalamus (Ebner et al., 2002; Wigger et al., 2004; Zhou et al., 2005); and (b) activation of AVP V1b receptors (especially in the amygdala) is involved in “anxiety”-related and “depression”-like behaviors in rats and mice (Griebel et al., 2002; Salome et al., 2006).”
BackgroundMethodInfluentialThe Role of Serotonin, Vasopressin, and Serotonin/Vasopressin Interactions in Aggressive Behavior
Morrison, T. R., & Melloni, R. H. (2014) · Current topics in behavioral neurosciences · doi:10.1007/7854_2014_283 · Cited by 57
“…while other components of the aggression circuit may regulate other forms of attack behavior (e.g., those necessary for the allocation of food) as shown by the results of Griebel et al. (2002), who studied defensive aggressive behaviors exhibited by mice in response to the presence of a rat.”
BackgroundResultA catalytic metal-free Ritter reaction to 3-substituted 3-aminooxindoles
Zhou, F., Ding, M., & Zhou, J. E. (2012) · Organic & Biomolecular Chemistry · doi:10.1039/c2ob25319d · Cited by 57
Moigneu, C., Abdellaoui, S., Ramos-Brossier, M., Pfaffenseller, B., Wollenhaupt-Aguiar, B., Cardoso, T. D. A., Camus, C., Chiche, A., Kuperwasser, N., da Silva, R. A., et al. (2023) · Nature Aging · doi:10.1038/s43587-022-00352-3 · Cited by 56
Iijima, M., Yoshimizu, T., Shimazaki, T., Tokugawa, K., Fukumoto, K., Kurosu, S., Kuwada, T., Sekiguchi, Y., & Chaki, S. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12699 · Cited by 55
“…was highlighted in reports that a V1B receptor antagonist, SSR149415, exhibits antidepressant and anxiolytic effects in several animal models of depression and anxiety, particularly under high-stress conditions (Griebel et al., 2002; Serradeil-Le Gal et al., 2002; Overstreet and Griebel, 2005).”
BackgroundVasopressin Antagonists as Anxiolytics and Antidepressants: Recent Developments
Simon, N. G., Guillon, C., Fabio, K. M., Heindel, N. D., Lu, S., Miller, M., Ferris, C. F., Brownstein, M., Garippa, C., & KOPPEL, G. A. (2008) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488908784534586 · Cited by 56
Louis, C., Cohen, C., Depoortère, R., & Griebel, G. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301036 · Cited by 55
“…of drugs that block receptors for CRF, leading to the pharmaceutical development of several compounds that are antagonists at the CRF1 receptor (Griebel et al, 2002c; Keck and Holsboer, 2001; Okuyama et al, 1999; Schulz et al, 1996; Millan et al, 2001; Lelas et al, 2004; Seymour et al, 2003).”
BackgroundResultInfluentialSelf-citationMajor depression: emerging therapeutics
Sen, S., & Sanacora, G. (2008) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20043 · Cited by 47
Piato, Â., Detanico, B. C., Jesus, J. F., Lhullier, F. L. R., Nunes, D. S., & Elisabetsky, E. (2008) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2008.04.018 · Cited by 55
“It has been shown that fluoxetine, desipramine, CRF1 antagonist and vasopressin V1b antagonist (Griebel et al., 2002a,b; Ducottet et al., 2003; Yalcin et al., 2005) are able to counteract the effects of UCMS on the state of the coat and/or the splash test.”
BackgroundSex differences in response to chronic mild stress and congenital serotonin deficiency
Sachs, B. D., Ni, J. R., & Caron, M. G. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.11.008 · Cited by 55
“In the current work, we employed the chronic unpredictable mild stress (CMS) model, which has been previously shown to induce depression- and anxiety-like behavior in rodents (Willner et al., 1987; Surget et al., 2009; Griebel et al., 2002).”
MethodTolstoy, P., Lee, S. X. Y., Sparr, C., & Ley, S. V. (2012) · Organic Letters · doi:10.1021/ol302119j · Cited by 54
Vasopressin and Oxytocin: Molecular, Cellular, and Clinical Advances
Zingg, H. H., Bourque, C. W., & Bichet, D. G. (1998) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-4871-3 · Cited by 53
Life-Long Hippocampal Neurogenesis: Environmental, Pharmacological and Neurochemical Modulations
Païzanis, E., Kelaï, S., Renoir, T., Hamon, M., & Lanfumey, L. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9330-0 · Cited by 52
“Similarly, under chronic treatment conditions, CRHR1 and V1b receptor antagonists, which are endowed with antidepressant-like properties in validated animal models [89, 90], exerted a positive influence on granule cell proliferation, thereby reversing the reduction in this process which had been caused by chronic mild…”
Anxiolytic and Sedative Effects of Dehydroeffusol fromJuncus effususin Mice
Liao, Y.-J., Zhai, H., Zhang, B., Duan, T., & Huang, J. (2010) · Planta Medica · doi:10.1055/s-0030-1250517 · Cited by 52
Egashira, N., Tanoue, A., Higashihara, F., Fuchigami, H., Sano, K., 三島, 健., Fukue, Y., Nagai, H., Takano, Y., Tsujimoto, G., et al. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300784 · Cited by 52
“Moreover, it has been reported that a selective V1bR antagonist produced anxiolytic- and antidepressantlike effects in rodents (Griebel et al, 2002; Serradeil-Le Gal et al, 2002) and reversed stress-induced suppression of neurogenesis in a mouse model of depression (Alonso et al, 2004).”
BackgroundSelf-citationAre neuropeptides relevant for the mechanism of action of SSRIs?
Gołyszny, M. J., & Obuchowicz, E. (2019) · Neuropeptides · doi:10.1016/j.npep.2019.02.002 · Cited by 52
Witkin, J. M., LIPPA, A. S., Smith, J. L., Jin, X., Ping, X., Biggerstaff, A., Kivell, B. M., Knutson, D. E., Sharmin, D., Pandey, K. P., et al. (2022) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2021.173321 · Cited by 51
Fodor, A., Klausz, B., Pintér, O., Daviu, N., Rabasa, C., Rotllant, D., Balázsfi, D., Kovács, K., Nadal, R. A., & Zelena, D. (2012) · Hormones and Behavior · doi:10.1016/j.yhbeh.2012.09.003 · Cited by 51
Isingrini, E., Surget, A., Belzung, C., Freslon, J., Frisbee, J. C., O’Donnell, J. M., Camus, V., & d’Audiffret, A. C. (2011) · Physiology & Behavior · doi:10.1016/j.physbeh.2011.04.002 · Cited by 50
Metadata
- Authors
- Griebel, G., Simiand, J., Serradeil-Le Gal, C., Wagnon, J., Pascal, M., Scatton, B., Maffrand, J.-P., & Soubrié, P.
- Affiliations
- Sanofi (France) (FR)
- Sanofi–Synthelabo Recherche, Avenue P. V.-Couturier, 92220 Bagneux, France; Sanofi–Synthelabo Recherche, Route d'Espagne, 31100 Toulouse, France; and Sanofi–Synthelabo Recherche, Rue du Professeur Blayac, 34000 Montpellier, France
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2002-04-16
- Volume
- 99
- Issue
- 9
- Pages
- 6370-6375
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC122955
- OpenAlex
- W2003547326
- Cited by
- 471
- References
- 31
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 6 · 2023: 6 · 2022: 8 · 2021: 12 · 2020: 14 · 2019: 10 · 2018: 15 · 2017: 8 · 2016: 20 · 2015: 18 · 2014: 29 · 2013: 16 · 2012: 21
- FWCI
- 10.11
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Neuroendocrine regulation and behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- non-peptide antagonists, anxiolytic effects, antidepressant effects, anxiety, depression, chronic mild stress, social defeat, traumatic stress, emotional processing, hypophysectomy, mood disorders
- MeSH terms
- Animals, Antidepressive Agents, Antidepressive Agents, Tricyclic, Anxiety, Behavior, Animal, Depression, Feeding Behavior, Fluoxetine, Imipramine, Indoles, Kinetics, Male, Mice, Inbred BALB C, Pyrrolidines, Stress, Physiological, Stress, Psychological, Time Factors, Anti-Anxiety Agents, Rats, Sprague-Dawley, Rats, Wistar, Risk Assessment, Antidepressive Agents, Second-Generation, Mice, Rats, Antidiuretic Hormone Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.